Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alette M Wessels

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentAlette M Wessels
The New England Journal of Medicine|August 11, 2021
Donanemab in Early Alzheimer's Disease. ReplyMark A Mintun, Alette M Wessels, John R Sims
European Journal of Pharmacology|April 9, 2008
Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetesAlette M Wessels, Philip Scheltens, Frederik Barkhof, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 9, 2022
Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimatesAlette M Wessels, Dorene M Rentz, Michael Case, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 30, 2022
Disease progression model using the integrated Alzheimer's Disease Rating ScaleIvelina Gueorguieva, Laiyi Chua, Brian A Willis, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 10, 2020
Clinical meaningfulness addressed at Alzheimer's Association Research RoundtableDorene M Rentz, Alette M Wessels, Lisa J Bain, et al.
Neurology. Clinical Practice|March 9, 2023
Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study FindingsAlette M Wessels, Ellen B Dennehy, Sherie A Dowsett, et al.
Drug Discovery Today|January 24, 2021
Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug developmentAlette M Wessels, Chris J Edgar, Pradeep J Nathan, et al.
The Journal of Prevention of Alzheimer'S Disease|March 5, 2025
Qualitative research and literature review support the integrated Alzheimer's Disease Rating Scale (iADRS) content validity in early symptomatic ADLaure Delbecque, Emma Elliott, Sophie Cleanthous, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 26, 2011
Diabetes and cognitive decline in elderly African Americans: a 15-year follow-up studyAlette M Wessels, Kathleen A Lane, Sujuan Gao, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentAlette M Wessels
The New England Journal of Medicine|August 11, 2021
Donanemab in Early Alzheimer's Disease. ReplyMark A Mintun, Alette M Wessels, John R Sims
European Journal of Pharmacology|April 9, 2008
Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetesAlette M Wessels, Philip Scheltens, Frederik Barkhof, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 9, 2022
Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimatesAlette M Wessels, Dorene M Rentz, Michael Case, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 30, 2022
Disease progression model using the integrated Alzheimer's Disease Rating ScaleIvelina Gueorguieva, Laiyi Chua, Brian A Willis, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 10, 2020
Clinical meaningfulness addressed at Alzheimer's Association Research RoundtableDorene M Rentz, Alette M Wessels, Lisa J Bain, et al.
Neurology. Clinical Practice|March 9, 2023
Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study FindingsAlette M Wessels, Ellen B Dennehy, Sherie A Dowsett, et al.
Drug Discovery Today|January 24, 2021
Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug developmentAlette M Wessels, Chris J Edgar, Pradeep J Nathan, et al.
The Journal of Prevention of Alzheimer'S Disease|March 5, 2025
Qualitative research and literature review support the integrated Alzheimer's Disease Rating Scale (iADRS) content validity in early symptomatic ADLaure Delbecque, Emma Elliott, Sophie Cleanthous, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 26, 2011
Diabetes and cognitive decline in elderly African Americans: a 15-year follow-up studyAlette M Wessels, Kathleen A Lane, Sujuan Gao, et al.
Pageof 4